209 related articles for article (PubMed ID: 25348781)
1. A comparative analysis of postoperative pancreatic fistulas after surgery with and without hyperthermic intraperitoneal chemoperfusion.
Downs-Canner S; Ding Y; Magge DR; Jones H; Ramalingam L; Zureikat A; Holtzman M; Ahrendt S; Pingpank J; Zeh HJ; Bartlett DL; Choudry HA
Ann Surg Oncol; 2015 May; 22(5):1651-7. PubMed ID: 25348781
[TBL] [Abstract][Full Text] [Related]
2. Repeat Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Recurrent Mucinous Appendiceal Adenocarcinoma: A Viable Treatment Strategy with Demonstrable Benefit.
Bhutiani N; Grotz TE; Concors SJ; White MG; Helmink BA; Raghav KP; Taggart MW; Beaty KA; Royal RE; Overman MJ; Matamoros A; Scally CP; Rafeeq S; Mansfield PF; Fournier KF
Ann Surg Oncol; 2024 Jan; 31(1):614-621. PubMed ID: 37872456
[TBL] [Abstract][Full Text] [Related]
3. Complexity of surgery and treatment burden in patients with peritoneal malignancy is not determined by addition of hyperthermic intraperitoneal chemotherapy.
Steffens D; Ansari N; Koh C; Ahmadi N; Solomon MJ; Hogan S; Karunaratne S; Anderson T; Harvey K; McBride K; Moran B
ANZ J Surg; 2024 Apr; 94(4):628-633. PubMed ID: 38450829
[TBL] [Abstract][Full Text] [Related]
4. Prognostic role of body composition in peritoneal carcinomatosis patients undergoing cytoreduction and hyperthermic intraperitoneal chemotherapy.
Song Y; Bae MI; Han DW; Park EJ; Park S; Ham SY
World J Surg Oncol; 2023 Oct; 21(1):345. PubMed ID: 37891626
[TBL] [Abstract][Full Text] [Related]
5. Impact of Successful Implementation of an Enhanced Recovery After Surgery Protocol for Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
Sun BJ; Yue TM; Xu N; Fowler C; Lee B
Ann Surg Oncol; 2023 Dec; 30(13):8156-8165. PubMed ID: 37684372
[TBL] [Abstract][Full Text] [Related]
6. Open versus Closed technique for administration of heated intraperitoneal chemotherapy (HIPEC): Morbidity and Mortality outcomes from a high-volume centre.
Hassan S; Dritsas S; O'Dwyer ST; Aziz O; Sutton P; Wang X; Fish R;
Eur J Surg Oncol; 2023 Sep; 49(9):106924. PubMed ID: 37179147
[TBL] [Abstract][Full Text] [Related]
7. Doxorubicin as Risk Factor for Fascial Dehiscence After CRS-HIPEC for Peritoneal Metastases.
Pizzolato E; Cenzi C; Tonello M; Pilati P; Sommariva A
Anticancer Res; 2024 Apr; 44(4):1553-1557. PubMed ID: 38537963
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for postoperative pancreatic fistula following non-traumatic, pancreatic surgery. Retrospective observational study.
Mostafa A; Habeeb TA; Neri V; Elshahidy TM; A Fiad A
Ann Ital Chir; 2023; 94():435-442. PubMed ID: 38051507
[TBL] [Abstract][Full Text] [Related]
9. Learning curve for minimal invasive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) procedures.
Durán-Martínez M; Gómez-Dueñas G; Rodriguez-Ortíz L; Sanchez-Hidalgo JM; Suárez AG; Casado-Adam Á; Rufián-Peña S; Andujar BR; Valenzuela-Molina F; Vázquez-Borrego MC; Romero-Ruiz A; Briceño-Delgado J; Arjona-Sánchez Á
Langenbecks Arch Surg; 2023 Apr; 408(1):146. PubMed ID: 37046100
[TBL] [Abstract][Full Text] [Related]
10. Incidence of incisional hernia in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: an observational clinical study from a tertiary oncology referral care center in India.
Ray M; Kumar A; Maranna H
World J Surg Oncol; 2024 May; 22(1):132. PubMed ID: 38760663
[TBL] [Abstract][Full Text] [Related]
11. Immune profile of patients with peritoneal carcinomatosis selected for CRS-HIPEC therapy.
Kleber J; Yang Zhou J; Weber F; Bitterer F; Hauer P; Kupke P; Kronenberg K; Geissler EK; Schlitt HJ; Hornung M; Hutchinson JA; Werner JM
Cancer Immunol Immunother; 2023 Nov; 72(11):3867-3873. PubMed ID: 37580610
[TBL] [Abstract][Full Text] [Related]
12. Postoperative C-reactive protein kinetics predict postoperative complications in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis.
Asmar AE; Bendavides M; Moreau M; Hendlisz A; Deleporte A; Khalife M; Donckier V; Liberale G
World J Surg Oncol; 2020 Nov; 18(1):311. PubMed ID: 33243287
[TBL] [Abstract][Full Text] [Related]
13. The impact of the extent of surgery on late adverse effects following cytoreductive surgery and HIPEC.
Ravn S; Grønfeldt JM; Thaysen HV; Iversen LH
Eur J Surg Oncol; 2024 Jan; 50(1):107105. PubMed ID: 38096698
[TBL] [Abstract][Full Text] [Related]
14. Prophylactic Cholecystectomy is Safe in Patients Undergoing Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy.
Hanna DN; Khajoueinejad N; Ghani MO; Hermina A; Mina A; Bailey CE; Cohen N; Labow D; Golas B; Sarpel U; Idrees K; Magge D
Am Surg; 2024 Jun; 90(6):1577-1581. PubMed ID: 38587264
[TBL] [Abstract][Full Text] [Related]
15. Does Hospital Operative Volume Influence the Outcomes of Patients After Heated Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis?
Chatani PD; Manzella A; Gribkova YY; Ecker BL; Beninato T; Kennedy T; Pitt HA; Alexander HR
Ann Surg Oncol; 2024 Feb; 31(2):1049-1057. PubMed ID: 37906385
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for gastrointestinal perforation and anastomotic leak in patients submitted to cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
Nogueiro J; Fathi NQ; Guaglio M; Baratti D; Kusamura S; Deraco M
Eur J Surg Oncol; 2023 Oct; 49(10):107020. PubMed ID: 37597284
[TBL] [Abstract][Full Text] [Related]
17. Intraoperative metabolic changes associated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Rubio-López JD; Durán-Martínez M; Moreno-Blázquez A; Rodríguez-Ortiz L; Rufián-Andújar B; Valenzuela-Molina F; Adam ÁC; Sánchez-Hidalgo JM; Rufián-Peña S; Romero-Ruiz A; Briceño-Delgado J; Arjona-Sánchez Á
Langenbecks Arch Surg; 2023 Jan; 408(1):34. PubMed ID: 36648571
[TBL] [Abstract][Full Text] [Related]
18. Weekend Discharge Is Not Associated With Increased Readmission After Hyperthermic Intraperitoneal Chemotherapy.
Florissi I; Radomski SN; Shou B; Cloyd JM; Kim A; Grotz T; Fournier K; Baumgartner JM; Lambert L; Abbott DE; Schwartz P; Staley CA; Clarke C; Dineen S; Patel SH; Wilson GC; Raoof M; Johnston FM; Greer JB
J Surg Res; 2024 Jan; 293():403-412. PubMed ID: 37806228
[TBL] [Abstract][Full Text] [Related]
19. Postoperative Opioid Use Is Associated with Increased Rates of Grade B/C Pancreatic Fistula After Distal Pancreatectomy.
Boyev A; Prakash LR; Chiang YJ; Childers CP; Jain AJ; Newhook TE; Bruno ML; Arvide EM; Dewhurst WL; Kim MP; Ikoma N; Lee JE; Snyder RA; Katz MHG; Tzeng CD; Maxwell JE
J Gastrointest Surg; 2023 Oct; 27(10):2135-2144. PubMed ID: 37468733
[TBL] [Abstract][Full Text] [Related]
20. HIPEC after neoadjuvant chemotherapy is associated with acceptable toxicity and favorable quality of life in newly diagnosed advanced ovarian cancer patients.
Menzies AV; Usher EC; Hsu FC; Levine EA; Lentz SS; Kelly MG
Gynecol Oncol; 2022 Nov; 167(2):234-238. PubMed ID: 36085091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
